Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas

NCT04089449 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT04089449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04089449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 6, 2019
Completion date
March 28, 2023
Enrollment
86 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, recurrent glioma